Aurinia Pharmaceuticals (AUPH) has released an update.
Aurinia Pharmaceuticals showcased data at the Congress of Clinical Rheumatology East 2024, emphasizing the safety and efficacy of LUPKYNIS in treating lupus nephritis, with findings indicating improved patient outcomes and reduced exposure to potential toxicities. Notably, Black patients treated with LUPKYNIS experienced better renal responses, underlining the drug’s effectiveness across diverse populations.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.
